Tag Archives: Development

Priority Review Vouchers Revitalizing Neglected Disease Drug Development

FILE – On Friday, July 20, 2018, the U.S. Food and Drug Administration approved GlaxoSmithKline’s Krintafel, a one-dose treatment to prevent relapses of malaria. (AP Photo/Kirsty Wigglesworth, File) Neglected tropical diseases (NTDs) impact more than one in six people worldwide, often the poorest, but are allocated less than 0.5 percent of global pharmaceutical investment. Yet, new… Read More »